Page 30 - Robert Kadlec News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Johnson & Johnson documented contamination risks at Baltimore plant months before vaccine doses were ruined By Christopher Rowland The Washington Post,Updated May 19, 2021, 11:46 a.m. Email to a Friend Robert Kramer, President and Chief Executive Officer of Emergent BioSolutions, speaks via videoconference during a hearing on Capitol Hill in Washington.Stefani Reynolds/Associated Press WASHINGTON - Johnson & Johnson documented contamination risks at a Baltimore biodefense plant in June 2020, seven months before a contamination problem ruined 15 million doses of coronavirus vaccine and deraile...

Emergent CEO: J&J vaccine production could resume in days Nathaniel Weixel © Getty Emergent CEO: J&J vaccine production could resume in days Emergent BioSolutions could resume manufacturing doses of Johnson & Johnson's coronavirus vaccine "within a matter of days," the company's CEO Robert Kramer told a House panel Wednesday. Democratic lawmakers on the House Coronavirus Crisis Subcommittee pressed Kramer on Emergent's ability to fix a host of manufacturing issues identified by a Food and Drug Administration (FDA) inspection of its Baltimore facility in April. At least one ...

Executives defend quality control at troubled COVID-19 vaccine plant Emily Kopp © Provided by Roll Call Rep. Mariannette Miller-Meeks (R-IA) listens as Robert Kramer, President and Chief Executive Officer of Emergent BioSolutions, speaks via videoconference during the hearing on the company's handling of COVID-19 vaccines. Executives at a vaccine contractor responsible for contaminating millions of vaccine doses defended its manufacturing quality Wednesday, even as new revelations emerged about the company’s lapses in sanitation, the role of a top Trump administration off...

Emergent BioSolutions Inc told U.S. regulators it aims as soon as July to correct the problems at its manufacturing facility that ruined millions of COVID-19…

J&J vaccine production could restart in U.S. 'within days,' Emergent executive testifies POLITICO 5 hrs ago By Sarah Owermohle © Stefani Reynolds/The New York Times via AP, Pool Robert Kramer, president and CEO of Emergent BioSolutions, speaks via videoconference during a hearing on Capitol Hill. Emergent BioSolutions could resume manufacturing Johnson & Johnson's Covid-19 vaccine within days, CEO Robert Kramer told a House panel Wednesday. The Food and Drug Administration ordered Emergent to pause production last month after a series of manufacturing problems at its Balt...